These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 28477068)
1. The role of miR-130a in cancer. Zhang HD; Jiang LH; Sun DW; Li J; Ji ZL Breast Cancer; 2017 Jul; 24(4):521-527. PubMed ID: 28477068 [TBL] [Abstract][Full Text] [Related]
2. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly. Zhang X; Huang L; Zhao Y; Tan W Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606 [TBL] [Abstract][Full Text] [Related]
3. Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance. Yang L; Li N; Wang H; Jia X; Wang X; Luo J Oncol Rep; 2012 Aug; 28(2):592-600. PubMed ID: 22614869 [TBL] [Abstract][Full Text] [Related]
4. Nuclear factor-κB-dependent microRNA-130a upregulation promotes cervical cancer cell growth by targeting phosphatase and tensin homolog. Feng Y; Zhou S; Li G; Hu C; Zou W; Zhang H; Sun L Arch Biochem Biophys; 2016 May; 598():57-65. PubMed ID: 27040383 [TBL] [Abstract][Full Text] [Related]
5. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells. Fujita Y; Kojima T; Kawakami K; Mizutani K; Kato T; Deguchi T; Ito M Prostate; 2015 Oct; 75(14):1568-78. PubMed ID: 26074357 [TBL] [Abstract][Full Text] [Related]
6. [Regulatory effects and associated mechanisms of miR-130a molecules on cisplatin resistance in ovarian cancer A2780 cell lines]. Li NW; Wang HJ; Yang LY; Jia XB; Chen C; Wang X Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Nov; 44(6):865-70. PubMed ID: 24490491 [TBL] [Abstract][Full Text] [Related]
7. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Xu N; Shen C; Luo Y; Xia L; Xue F; Xia Q; Zhang J Biochem Biophys Res Commun; 2012 Aug; 425(2):468-72. PubMed ID: 22846564 [TBL] [Abstract][Full Text] [Related]
8. The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Humphries B; Yang C Oncotarget; 2015 Mar; 6(9):6472-98. PubMed ID: 25762624 [TBL] [Abstract][Full Text] [Related]
9. Role of microRNAs in drug-resistant ovarian cancer cells. Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650 [TBL] [Abstract][Full Text] [Related]
10. [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer]. Yang LY; Wang HJ; Jia XB; Wang X; Luo J; Zhang XY Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Jan; 43(1):60-4. PubMed ID: 22455133 [TBL] [Abstract][Full Text] [Related]
11. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. Chen Z; Ma T; Huang C; Zhang L; Lv X; Xu T; Hu T; Li J Cell Signal; 2013 Dec; 25(12):2693-701. PubMed ID: 24018051 [TBL] [Abstract][Full Text] [Related]
12. Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. Ramalho-Carvalho J; Martins JB; Cekaite L; Sveen A; Torres-Ferreira J; Graça I; Costa-Pinheiro P; Eilertsen IA; Antunes L; Oliveira J; Lothe RA; Henrique R; Jerónimo C Cancer Lett; 2017 Jan; 385():150-159. PubMed ID: 27984115 [TBL] [Abstract][Full Text] [Related]
13. [Expression of MiR-130a in Serum Samples of Patients with Epithelial Ovarian Cancer and Its Association with Platinum Resistance]. Chen C; Wang HJ; Yang LY; Jia XB; Xu P; Chen J; Liu Y Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Jan; 47(1):60-3. PubMed ID: 27062783 [TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Yang H; Kong W; He L; Zhao JJ; O'Donnell JD; Wang J; Wenham RM; Coppola D; Kruk PA; Nicosia SV; Cheng JQ Cancer Res; 2008 Jan; 68(2):425-33. PubMed ID: 18199536 [TBL] [Abstract][Full Text] [Related]
15. Review of miR-200b and cancer chemosensitivity. Feng B; Wang R; Chen LB Biomed Pharmacother; 2012 Sep; 66(6):397-402. PubMed ID: 22795796 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA-130b promotes proliferation and EMT-induced metastasis via PTEN/p-AKT/HIF-1α signaling. Chang RM; Xu JF; Fang F; Yang H; Yang LY Tumour Biol; 2016 Aug; 37(8):10609-19. PubMed ID: 26861561 [TBL] [Abstract][Full Text] [Related]
17. miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-κB in high-grade serous ovarian carcinoma. Wang Y; Zhang X; Tang W; Lin Z; Xu L; Dong R; Li Y; Li J; Zhang Z; Li X; Zhao L; Wei JJ; Shao C; Kong B; Liu Z Cell Death Differ; 2017 Dec; 24(12):2089-2100. PubMed ID: 28800130 [TBL] [Abstract][Full Text] [Related]
18. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326 [TBL] [Abstract][Full Text] [Related]
19. MiR-106a: Promising biomarker for cancer. Pan YJ; Zhuang Y; Zheng JN; Pei DS Bioorg Med Chem Lett; 2016 Nov; 26(22):5373-5377. PubMed ID: 27780637 [TBL] [Abstract][Full Text] [Related]
20. Regulation of the MIR155 host gene in physiological and pathological processes. Elton TS; Selemon H; Elton SM; Parinandi NL Gene; 2013 Dec; 532(1):1-12. PubMed ID: 23246696 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]